Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Ishares Msci Thailand Etf (THD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Ishares Msci Thailand Etf — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Ishares Msci Thailand Etf trades at $71.15 (market cap $424.09M). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 17.7× Ishares Msci Thailand Etf's market cap, and Ishares Msci Thailand Etf is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Ishares Msci Thailand Etf for 67 Days on average.
| SYRE | THD | |
|---|---|---|
Market Cap | $7.52B | $424.09M |
Volume | 1,441,031 | 1,217,048 |
Sector | Health | Broad Market / Factor |
52-Week High | $108.92 | $75.06 |
52-Week Low | $22.18 | $57.86 |
Typical Hold Time | 0 Days | 67 Days |
Enterprise Value | $6.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
THD (iShares MSCI Thailand ETF) trades at $71.17, down 0.27% with bearish technical signals across moving averages and oscillators. Short interest surged 90.6% in September 2026 (Defense World, 2026-10-01), indicating rising bearish sentiment. The ETF has delivered strong 38% returns over the past year (Seeking Alpha, 2026-07-09) but faces headwinds from capital rotation away from Asian AI-related markets.
Outlook remains cautious given technical weakness and elevated short positioning. Investment opportunity exists for exposure to Thailand's AI hardware plays like Delta Electronics, but vulnerability to profit-taking and regional capital outflows presents significant near-term risks for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Ishares Msci Thailand Etf
THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →
